Nestlé Health Science chooses Valbiotis to develop and market TOTUM-63

Companies to work on a combination of five plant extracts to reduce the risk of Type 2 Diabetes

Sébastien Peltier, Valbiotis CEO. Photo credit Sylvie Curty

Valbiotis, the French R&D biotech company, has signed a strategic partnership with Nestlé Health Science for the development and commercialisation of TOTUM-63, an innovative and patented product to reduce the risk of developing Type 2 Diabetes.

The companies described TOTUM-63 as a combination of five plant extracts specifically designed to reduce the risk of developing Type 2 Diabetes on prediabetic subjects.

“The research and development that Valbiotis is doing is very promising. We look forward to working together to realise the commercialisation of TOTUM-63, an innovative approach to reducing the risk of Type 2 Diabetes,” said Hans-Juergen Woerle, Chief Science & Medical Officer of Nestlé Health Science.

Under the terms of the agreement, Valbiotis grants Nestlé Health Science exclusive and global commercial rights to use TOTUM-63 in the prediabetes and Type 2 Diabetes market.

The research and development that Valbiotis is doing is very promising

The partnership will support Valbiotis’ work in several ways, including funding the latest clinical development phase until health claims are obtained by regulatory authorities in the US and Europe.

Sébastien Peltier, Valbiotis CEO, commented: “Nestlé Health Science is an ideal strategic partner for Valbiotis. Its global reach, strategic intent to develop science-based nutritional health solutions and focus on fighting metabolic disorders like diabetes will be instrumental to TOTUM-63’s worldwide commercialisation success.”

Peltier pointed out that the deal with Nestlé arrives just five years after the creation of Valbiotis and is “a recognition of the hard work, commitment and vision of our team”.

Headquartered in Périgny, southern France, Valbiotis entered the market in 2014 to develop a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.

Valbiotis has formed numerous partnerships with top academic centres and operates from three sites in France: Périgny, La Rochelle and Riom.

Beyond this strategic partnership on TOTUM-63, Valbiotics intends to pursue its other R&D programs: TOTUM-070 to reduce blood LDL-cholesterol; TOTUM-8541 to reduce blood pressure, and TOTUM-4481 in fatty liver disease, a condition with high risk of developing NASH.

Companies